Skip to main content

Table 4 Demographic and medication data between the rs1045642 C–rs2235048 T allele carrier group and the rs1045642 Non-C–rs2235048 Non-T allele carrier group in participants treated with aripiprazole monotherapy

From: Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia

 

rs1045642 T/T, C/T

rs2235048 C/C, C/T

rs1045642 C/C

rs2235048 T/T

P

Age (years)

46.74 ± 14.03

42.18 ± 13.21

.277

BMI (kg/m2)

25.41 ± 5.32

24.43 ± 4.43

.625

PANSS total score

71.32 ± 15.33

72.82 ± 17.83

.761

Disease duration (years)

16.10 ± 13.34

16.94 ± 10.66

.823

CPZeqa (mg/day)

445.97 ± 210.37

500.00 ± 149.48

.354

BPDeqb (mg/day)

1.13 ± 2.78

0.47 ± 0.87

.348

DZPeqc (mg/day)

3.93 ± 5.47

6.89 ± 7.50

.124

  1. Data are presented as the mean ± standard deviation
  2. BMI body mass index, PANSS Positive and Negative Syndrome Scale
  3. aThe daily doses of antipsychotic drugs were converted to an approximate chlorpromazine equivalent
  4. bThe daily doses of anticholinergic antiparkinsonian drugs were converted to an approximate biperiden equivalent
  5. cThe daily doses of benzodiazepine were converted to an approximate diazepam equivalent